Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intravitreal injection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    395 result(s) found for: Intravitreal injection. Displaying page 1 of 20.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006265-93 Sponsor Protocol Number: AVO1 Start Date*: 2009-03-11
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
    Medical condition: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000103-27 Sponsor Protocol Number: Eylea-2014 Start Date*: 2014-03-12
    Sponsor Name:
    Full Title: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration (AMD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004203-39 Sponsor Protocol Number: FNKV-OFT-2013-1 Start Date*: 2014-04-03
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy
    Medical condition: prolipherative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005700-24 Sponsor Protocol Number: SC Start Date*: 2015-08-17
    Sponsor Name:Abteilung für Augenheilkunde, AKH Linz
    Full Title: Aqueous Humor cytokine Levels following intravitreal ranibizumab or dexamethasone therapy in patients with diabetic macular edema
    Medical condition: Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005556-25 Sponsor Protocol Number: OFT-ETAMSILATO-4.2.2 Start Date*: 2015-05-11
    Sponsor Name:Investigacion Independiente
    Full Title: Open extension study for patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulatedcontrolled treatment to evaluate safety and efficacy o...
    Medical condition: Aged related macula degeneration (ARMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002155-10 Sponsor Protocol Number: AHM001 Start Date*: 2016-05-29
    Sponsor Name:FISEVI Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
    Full Title: Effect of topical bromfenac 0.9 mg / ml in the perception of pain after intravitreal injection of drugs
    Medical condition: Following the intravitreal injection of various drugs, very common procedure in clinical practice in ophthalmology, pain often occurs to varying degrees, although in most cases it is a painless pro...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10067261 Ocular pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003976-36 Sponsor Protocol Number: CBPD952ABE02 Start Date*: 2006-09-01
    Sponsor Name:Professor Anita Leys - Dienst Oftalmologie UZ St. Rafaël
    Full Title: An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predomi...
    Medical condition: Male and female patients ≥50 years of age with subfoveal choroidal neovascularisation lesions secondary to age related macular degeneration, either predominantly classic or occult with no classic c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005462-12 Sponsor Protocol Number: LUTA1 Start Date*: 2007-12-11
    Sponsor Name:St. Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal ranibizumab (Lucentis®) combined with transpupillary thermotherapy (TTT) in patients with neovascular age-related macular dege...
    Medical condition: Age-related macular degeneration (AMD) is the leading cause of visual impairment and social blindness in people 60 years or older. Approximately 80% of patients with severe visual loss exhibit neov...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000658-30 Sponsor Protocol Number: prot PDR 1 Start Date*: 2007-03-02
    Sponsor Name:Royal Victoria Eye and Ear hospital
    Full Title: Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy.
    Medical condition: Proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000585-21 Sponsor Protocol Number: prot RG 1 Start Date*: Information not available in EudraCT
    Sponsor Name:Royal Victoria Eye and Ear hospital
    Full Title: Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma.
    Medical condition: Rubeotic glaucoma secondary to ischaemic proliferative retinopathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001914-34 Sponsor Protocol Number: 01052006 Start Date*: 2006-08-30
    Sponsor Name:Bert Mueller, Dep. Ophthalmology
    Full Title: Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin)
    Medical condition: neovascular age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001385-14 Sponsor Protocol Number: IOBA-01-2004 Start Date*: 2006-01-23
    Sponsor Name:IOBA. FACULTAD DE MEDICINA
    Full Title: Evaluacion de la eficacia y seguridad de la inyección intravítrea de triamcinolona en el tratamiento del edema difuso del diabético
    Medical condition: DIFFUSE DIABETIC MACULAR OEDEMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003170-99 Sponsor Protocol Number: IVB JSA Start Date*: 2007-07-24
    Sponsor Name:UNIVERSITA DEGLI STUDI DI UDINE
    Full Title: Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration
    Medical condition: Exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061763 Chorioretinal disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005400-14 Sponsor Protocol Number: WONR1001 Start Date*: 2008-07-25
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: PERIOPERATIVE INTRAVITREAL TRIAMCINOLONE IN PHAKOEMULSIFICATION FOR CONCURRENT CLINICALLY SIGNIFICANT DIABETIC MACULAR OEDEMA
    Medical condition: Diabetic Maculopathy: Clinically significant macular oedema To understand the effects of intravitreal triamcinolone (IVTA) in the treatment of clinically significant macular edema (CSME) in diabet...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001781-15 Sponsor Protocol Number: IOBA-04-2012 Start Date*: 2012-07-31
    Sponsor Name:IOBA, Universidad de Valladolid
    Full Title: Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study)
    Medical condition: choroidal neovascularization associated to myopia magna
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017540-13 Sponsor Protocol Number: Start Date*: 2010-07-27
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A Phase IV Open-Labelled Prospective Pilot Study of Intravitreal Macugen (pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME study)
    Medical condition: Ischaemic diabetic macular oedema.
    Disease: Version SOC Term Classification Code Term Level
    12 10057915 diabetic macular oedema SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000961-10 Sponsor Protocol Number: NITRO Protocol Start Date*: 2011-12-07
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals Trust
    Full Title: Neoadjuvant IntraviTreal Ranibizumab treatment in high risk Ocular melanoma patients: A two stage single centre Phase II single arm study (NITRO Trial)
    Medical condition: Uveal Melanoma (requiring enucleation)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001869-41 Sponsor Protocol Number: OKHN1005 Start Date*: 2011-08-24
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: An exploratory study of ranibizumab (Lucentis) for treatment of uveitic patients with refractory cystoid macular oedema. 'The LIMO study'
    Medical condition: Uveitic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000397-45 Sponsor Protocol Number: OY060301 Start Date*: 2005-06-02
    Sponsor Name:Queen's Medical centre
    Full Title: Randomised Controlled Trial Of Intravitreal Triamcinolone In Patients With Diabetic Macular Oedema Refractory To Laser Treatment
    Medical condition: Diabetic macular oedema affecting vision and refractory to laser treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003272-12 Sponsor Protocol Number: SIVS1012 Start Date*: 2014-04-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
    Medical condition: Proliferative Diabetic Retinopathy (PDR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA